Lifeward Ltd. (LFWD)
| Market Cap | 16.99M +42.8% |
| Revenue (ttm) | 21.82M -10.7% |
| Net Income | -30.83M |
| EPS | -17.00 |
| Shares Out | 2.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,916 |
| Open | 6.13 |
| Previous Close | 6.06 |
| Day's Range | 6.00 - 6.53 |
| 52-Week Range | 4.14 - 9.61 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 20.00 (+233.33%) |
| Est. Earnings | Nov 13, 2026 |
About LFWD
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG ... [Read more]
Financial Performance
In 2025, Lifeward's revenue was $22.03 million, a decrease of -14.14% compared to the previous year's $25.66 million. Losses were -$19.91 million, -31.19% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LFWD stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 233.33% from the latest price.
News
Lifeward’s ReWalk exoskeleton shows sustained long-term home use in study
Lifeward (LFWD) announced the publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of t...
Lifeward's ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was use d for a median of 33 months, with no reported falls or exoskeleto...
Lifeward Proxy statement: Proxy filing
Lifeward filed a proxy statement on September 25, 2026, providing details for shareholder voting and corporate governance matters.
Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use
Lifeward Proxy statement: Proxy filing
Lifeward filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.
Lifeward Slides: Investor presentation
Lifeward has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Lifeward CEO Mark Grant to depart, Josh Hexter named interim CEO
Lifeward (LFWD) announced the appointment of Josh Hexter as interim CEO effective September 1 and Rami Aviram as CFO effective November 1. Hexter succeeds Mark Grant, who has chosen to…
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy Experienced leadership team to build on established c...
Lifeward Earnings release: Q2 2026
Lifeward released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Lifeward Quarterly report: Q2 2026
Lifeward has published its Q2 2026 quarterly earnings report on August 14, 2026.
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commerc...
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of c...
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to br...
Lifeward files to sell 2.07M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.07M ordinay shares. The company is not selling any shares under…
Lifeward Registration statement: Registration filing
Lifeward filed a registration statement on August 3, 2026, providing details about a securities offering with the SEC.
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial ...
Lifeward appoints Keith Rose as chief medical officer
Lifeward (LFWD) announced the appointment of Keith Rose as chief medical officer. Rose, who previously served as VP, medical affairs and medical director, Neurosciences at Lifeward, will lead the comp...
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic diseas...
Lifeward Earnings Call Transcript: Q1 2026
Revenue declined year-over-year due to AlterG shipment delays, but ReWalk sales grew 11% and international expansion continued. Liquidity improved with new financing and the Oratech acquisition, while operational efficiency gains offset lower revenue.
Lifeward Earnings release: Q1 2026
Lifeward released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Lifeward Quarterly report: Q1 2026
Lifeward has published its Q1 2026 quarterly earnings report on May 15, 2026.
Lifeward Reports First Quarter 2026 Financial Results
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lea...
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of co...
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles...